BRPI0908276B8 - uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite - Google Patents

uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite

Info

Publication number
BRPI0908276B8
BRPI0908276B8 BRPI0908276A BRPI0908276A BRPI0908276B8 BR PI0908276 B8 BRPI0908276 B8 BR PI0908276B8 BR PI0908276 A BRPI0908276 A BR PI0908276A BR PI0908276 A BRPI0908276 A BR PI0908276A BR PI0908276 B8 BRPI0908276 B8 BR PI0908276B8
Authority
BR
Brazil
Prior art keywords
drug
prevention
manufacture
treatment
antagonist antibody
Prior art date
Application number
BRPI0908276A
Other languages
English (en)
Inventor
Louis Shelton David
Machin Ian
Zeller Joerg
Todd Poulsen Kristian
Corradini Laura
Original Assignee
Labrys Biologics Inc
Pfizer Ltd
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908276(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Labrys Biologics Inc, Pfizer Ltd, Teva Pharmaceuticals Int Gmbh filed Critical Labrys Biologics Inc
Publication of BRPI0908276A2 publication Critical patent/BRPI0908276A2/pt
Publication of BRPI0908276B1 publication Critical patent/BRPI0908276B1/pt
Publication of BRPI0908276B8 publication Critical patent/BRPI0908276B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de composto para tratar dor inflamatória. a invenção diz respeito de um anticorpo anti-cgrp para uso na prevenção e/ou tratamento de dor inflamatória e/ou sintomas de dor inflamatória, e a um método de tratar e/ou prevenir dor inflamatória e/ou sintomas de dor inflamatória usando um anticorpo anti-cgrp.
BRPI0908276A 2008-03-04 2009-03-03 uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite BRPI0908276B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3356808P 2008-03-04 2008-03-04
US61/033,568 2008-03-04
PCT/IB2009/050849 WO2009109908A1 (en) 2008-03-04 2009-03-03 Methods of treating inflammatory pain

Publications (3)

Publication Number Publication Date
BRPI0908276A2 BRPI0908276A2 (pt) 2015-08-18
BRPI0908276B1 BRPI0908276B1 (pt) 2020-11-10
BRPI0908276B8 true BRPI0908276B8 (pt) 2021-05-25

Family

ID=40823474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908276A BRPI0908276B8 (pt) 2008-03-04 2009-03-03 uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite

Country Status (19)

Country Link
US (6) US8298536B2 (pt)
EP (2) EP3115062A1 (pt)
JP (3) JP5745861B2 (pt)
KR (1) KR101304085B1 (pt)
CN (2) CN101959529A (pt)
AU (1) AU2009220897B2 (pt)
BR (1) BRPI0908276B8 (pt)
CA (1) CA2716799C (pt)
DK (1) DK2265288T3 (pt)
ES (1) ES2584907T3 (pt)
HK (1) HK1232130A1 (pt)
IL (1) IL207439B (pt)
MX (1) MX2010009724A (pt)
NZ (1) NZ587297A (pt)
PL (1) PL2265288T3 (pt)
PT (1) PT2265288T (pt)
RU (1) RU2467765C2 (pt)
WO (1) WO2009109908A1 (pt)
ZA (1) ZA201006070B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
EP2265287B1 (en) 2008-03-04 2018-09-05 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
US8298536B2 (en) * 2008-03-04 2012-10-30 Pfizer Limited Methods of treating inflammatory pain
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2470207A1 (en) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
EA201891284A1 (ru) * 2011-05-20 2018-11-30 Олдербайо Холдингз Ллк Композиции антител против cgrp и их применение
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
WO2013168004A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
RU2535095C2 (ru) * 2013-01-09 2014-12-10 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Композиция для трансдермальной доставки в организм лекарственных веществ и лекарственная форма на ее основе
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JP6508670B2 (ja) * 2014-12-26 2019-05-08 国立大学法人広島大学 軟骨変性抑制剤
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
EP3337523B1 (en) * 2015-08-19 2022-04-27 University of Iowa Research Foundation Preventative therapy for post-traumatic osteoarthritis
EP3408290A1 (en) 2016-01-28 2018-12-05 Eli Lilly and Company Cgrp antibodies and uses thereof
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
WO2019050974A1 (en) * 2017-09-05 2019-03-14 Kansas State University Research Foundation ANALGESIC FORMULATION FOR THE CONTROL OF PAIN IN DOGS
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
US11407838B2 (en) 2018-04-02 2022-08-09 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
WO2021015342A1 (ko) * 2019-07-24 2021-01-28 의료법인 성광의료재단 Trpv4 길항제를 포함하는 척수 손상 예방 또는 치료용 조성물
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN112142838B (zh) * 2020-07-23 2021-11-16 杭州傲锐生物医药科技有限公司 一种卡利普多人工抗原及其多抗和应用
CN115181099B (zh) * 2021-04-02 2024-01-16 南京舒鹏生物科技有限公司 一种醌类化合物及其药学应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EA008108B1 (ru) * 2001-09-19 2007-04-27 Алтана Фарма Аг Комбинация нспвлс и ингибитора pde-4
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
EP1501929B1 (de) * 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
AU2007275577A1 (en) * 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8298536B2 (en) * 2008-03-04 2012-10-30 Pfizer Limited Methods of treating inflammatory pain

Also Published As

Publication number Publication date
CA2716799A1 (en) 2009-09-11
NZ587297A (en) 2012-10-26
AU2009220897B2 (en) 2014-09-18
BRPI0908276B1 (pt) 2020-11-10
CA2716799C (en) 2018-05-22
RU2467765C2 (ru) 2012-11-27
US8298536B2 (en) 2012-10-30
AU2009220897A1 (en) 2009-09-11
JP5745861B2 (ja) 2015-07-08
IL207439A0 (en) 2010-12-30
JP2015145420A (ja) 2015-08-13
WO2009109908A1 (en) 2009-09-11
PT2265288T (pt) 2016-07-14
HK1232130A1 (zh) 2018-01-05
IL207439B (en) 2019-01-31
KR101304085B1 (ko) 2013-09-05
JP2017105835A (ja) 2017-06-15
JP2011513386A (ja) 2011-04-28
RU2010136974A (ru) 2012-03-10
EP2265288A1 (en) 2010-12-29
US20170073398A1 (en) 2017-03-16
US20200148752A1 (en) 2020-05-14
US20180305443A1 (en) 2018-10-25
JP6363242B2 (ja) 2018-07-25
WO2009109908A8 (en) 2010-08-19
PL2265288T3 (pl) 2017-01-31
BRPI0908276A2 (pt) 2015-08-18
US20130295088A1 (en) 2013-11-07
CN101959529A (zh) 2011-01-26
EP3115062A1 (en) 2017-01-11
KR20100112195A (ko) 2010-10-18
ZA201006070B (en) 2011-06-29
MX2010009724A (es) 2010-09-28
EP2265288B1 (en) 2016-05-11
US20220017608A1 (en) 2022-01-20
ES2584907T3 (es) 2016-09-30
US20110054150A1 (en) 2011-03-03
DK2265288T3 (en) 2016-06-06
CN106110321A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
UA109658C2 (xx) Антитіло проти cgrp
GT200800098A (es) Anticuerpos anti mn y metodos para su utilización
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
TN2012000136A1 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
BR112013029330A8 (pt) uso de anticorpo imunoconjugado maytansinoide anti-cd19 para o tratamento de sintomas de doenças de célula-b
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201001865A1 (ru) Противовоспалительные агенты
EA201100609A1 (ru) Способы лечения воспаления
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
TR201907261T4 (tr) DKK-1 antikorları.
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
BR112014000810A8 (pt) Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
BRPI0906172A2 (pt) Agentes de depleção de células b, como anticorpos anti-cd20 ou fragmentos dos mesmos para o tratamento da síndrome da fadiga crônica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: LABRYS BIOLOGICS INC. (US)

B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF